Revance Therapeutics Inc (NAS:RVNC)
$ 2.87 -0.02 (-0.69%) Market Cap: 299.77 Mil Enterprise Value: 500.56 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics, Inc. - Special Call Transcript

Jan 10, 2020 / 01:30PM GMT
Release Date Price: $19.5 (+18.29%)
Operator

Welcome to the Revance Therapeutics call discussing the company's exclusive U.S. distribution agreement for TEOXANE's line of FDA-approved dermal fillers. (Operator Instructions) As a reminder, this conference is being recorded today, January 10, 2020.

I would now like to turn the conference over to Jeanie Herbert, Senior Director of Investor Relations. Please go ahead.

Jeanie D. Herbert
Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications

Thank you, Kevin. With me on today's call from Revance Therapeutics is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Sjuts; and Vice President of Medical Affairs, Aesthetics and Therapeutics, Conor Gallagher.

This morning, Revance Therapeutics announced a transformative aesthetics portfolio transaction with TEOXANE SA for the exclusive U.S. distribution rights of TEOXANE's RHA range of FDA-approved dermal fillers. If you have not received this news release and would like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot